Hormonal
Weekly subcutaneous semaglutide (2.4 mg) significantly improves functional capacity and reduces heart failure hospitalizations in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.
If you have heart failure with preserved ejection fraction (HFpEF) and obesity, ask your doctor about weekly semaglutide injections (2.4 mg). This treatment has been shown to significantly improve your ability to perform daily activities, reduce your body weight, and lower your risk of being hospitalized for heart failure.
After a mean follow-up of 52 weeks, the KCCQ-CSS was improved by 16.6 points with semaglutide and 8.7 points with placebo (7.8 points, 95% confidence interval 4.8-10.9), and the change in body weight was −13.3% with semaglutide and −2.6% with placebo (−10.7 %, 95% confidence interval −11.9 to −9.4). ... adjudicated events of hospitalization or an urgent visit for heart failure were reduced (hazard ratio 0.27, 95% confidence interval 0.12-0.56).
Why this rating
Based on the STEP-HFpEF trial, a randomized clinical trial, though the paper notes some concerns about the SUMMIT trial for tirzepatide.
Source
Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health
Chern-En Chiang et al. · Journal of the Chinese Medical Association · 2025
DOI 10.1097/jcma.0000000000001263
More from this paper
- Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major adverse cardiovascular events (MACE), cardiovascular death, and all-cause death in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.Strong
- Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major renal events, cardiovascular death, and all-cause death in patients with type 2 diabetes and chronic kidney disease.Strong
- Weekly subcutaneous semaglutide (2.4 mg) significantly reduces body weight and major adverse cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →